01
Clinical
Oncolytic adenovirus delivery of neoantigens sensitizes low-mutation tumors to anti-PD-1 therapy and prevents metastasis - Nature
A Nature study shows that oncolytic adenovirus delivery of neoantigens can sensitize low-mutation tumors to anti-PD-1 therapy and prevent metastasis. This offers a potential solution for 'cold' tumors with low neoantigen burden, leveraging viral vectors to enhance antigen presentation and immune infiltration.